THE Therapeutic Goods Administration (TGA) has granted Section 19A approval to authorise Mundipharma to import and supply Nyxoid naloxone 1.8mg nasal spray from the UK, to address shortages in Australia.
The regulator has forecast that a shortage of the Australian Register of Therapeutic Goods (ARTG) listed, Nyxoid naloxone hydrochloride dihydrate 2.2mg/actuation nasal spray vial, will remain in short supply until 15 Nov.
Naloxone supply issues emerged a little over a month after the National Take Home Naloxone (THN) program was rolled out (PD 27 Jun), following the success of the pharmacy-based program in NSW, Western Australia and South Australia.
Pharmacies participating in the THN program are required to source naloxone through their usual supply channel, such as a pharmaceutical wholesaler, and claim for it once the medicine has been supplied free of charge to an individual.
The THN initiative allows any person across Australia to access free naloxone without prescription, with the aim of making it free and easily available for people at risk of an overdose such as illicit drug users and people who use prescription opioid medications, as well as their carers, friends, family and the community.
All sites participating in the program must submit data as part of their claims, to allow the Commonwealth Government and State Health Departments to monitor the supply of naloxone under the program.
Fees for supply of Naloxone range from around $40 to $50 depending on the product supplied - for more information and to register see ppaonline.com.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 23 Aug 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 23 Aug 22
